Breaking Finance News

Biotest (ETR:BIO) target price raised to 18.00EUR, reported today by equinet AG

Just yesterday Biotest (ETR:BIO) traded 0.69% higher at 13.36EUR. Biotest’s 50-day average is 152.14EUR and its two hundred day average is 144.02EUR. The last stock close is down 11.04% relative to the 200-day average, compared with the S&P 500 which has fallen -0.01% over the same period. 218,854 shares of BIO exchanged hands, up from ann average volume of 119,155.

equinet AG upped the estimated target of Biotest (ETR:BIO) to 18EUR, stating a possible upside of 0.35%,

On 8/14/2016, equinet AG reported on Biotest(ETR:BIO) upped the target price from 0.00EUR to 18.00EUR that suggested an upside of 0.35%.

Recent Performance Graphic:

Biotest (ETR:BIO)

A total of 2 firms have reported on the company. Zero rate the stock a strong buy, 0 rate the stock a buy, 0 analysts rate the company a hold, 0 rate the stock to underperform, and lastly 0 firmsrate the company as sell with a 12-month target price of 176.00EUR

Biotest has a P/E of 49 with a 52 week low of 122.03EUR and a one-year high of 161.70EUR. Biotest’s market capitalization is presently 0.0 EUR.

About Biotest (ETR:BIO)

Biotest AG is a Germany-based international supplier of biological medications. It diversifies its activities into three business segments: Therapy segment, Plasma and Services segment, as well as Other segment. Its Therapy segment comprises the development and production of blood plasma-based immunoglobulin clotting factors and albumins, which are used in diseases of the immune system, hematological diseases, and intensive care medicine. It also includes the preclinical and clinical development of monoclonal antibodies, indications for which include rheumatoid arthritis and blood cancer. Furthermore, the Company’s Plasma and Services segment includes the areas of plasma sales and toll manufacturing. Its Other segment, and includes retail business and costs that cannot be allocated to the Therapy segment or the Plasma and Services segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.